EvatuatingCT1812 in Subjects with mild to moderate dementia with Lewy Bodies

Recruiting
50 years - 85 years
All
3 participants needed
1 Location

Brief description of study

The purpose of this clinical study is to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812. The study will also test how well CT1812 will treat mild to moderate dementia with Lewy Bodies.

Detailed description of study

Your participation in this clinical study is expected to last for 210 days (30 weeks, including a 42-day Screening period and the 28-day follow-up examination). During this time, you will receive the study drug for 182 days (26 weeks). You will have 12 visits to the study site during this time (including the Screening Visit). Beginning at Day 1 you will have visits every 2 weeks though Day 70 (Week 19) and then visits every 4 weeks until Day 182, with the final Safety Follow-up Visit about 4 weeks after your last dose of the study drug on Day 210.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dementia
  • Age: 50 years - 85 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 851897

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center